Compare COCP & GFAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COCP | GFAI |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | 1657 |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 15.9M |
| IPO Year | 2011 | N/A |
| Metric | COCP | GFAI |
|---|---|---|
| Price | $1.07 | $0.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $4.50 |
| AVG Volume (30 Days) | 44.4K | ★ 161.1K |
| Earning Date | 05-15-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,712,091.00 | N/A |
| Revenue This Year | N/A | $14.12 |
| Revenue Next Year | N/A | $10.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.31 |
| 52 Week High | $2.03 | $1.38 |
| Indicator | COCP | GFAI |
|---|---|---|
| Relative Strength Index (RSI) | 58.44 | 37.63 |
| Support Level | $0.99 | $0.31 |
| Resistance Level | $1.11 | $0.42 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 93.14 | 17.54 |
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific region. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, and Corporate and others. The majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions. Geographically, the company generates maximum revenue from Thailand.